FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:1266-1268 October 21, 1993 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Almost two decades have passed since Kohler and Milstein first applied somatic-cell hybridization to the production of specific murine immunoglobulins (monoclonal antibodies)¹. In clinical oncology, the use of monoclonal techniques has had a substantial effect on diagnostic methods. Murine monoclonal antibodies against tumor-associated antigens have permitted immunophenotyping of lymphoreticular neoplasms, immunocytochemical analysis of tumor metastases, and the development of assays for several circulating tumor markers, including CA-125 and prostate-specific antigen. Recently, one radiolabeled murine monoclonal antibody was approved by the Food and Drug Administration for the preoperative localization of metastatic ovarian and colorectal cancers.

Despite the essentially unlimited supply . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.